US › Healthcare

Biohaven Ltd. (BHVN)

US · Healthcare · Biotechnology

$13.75+2.84%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-130.5M
Profit YoY
+41.1%
EPS
$-0.69
EPS estimate
$-0.76

EPS came in at -0.69 against a street estimate of -0.76 — a beat of 9.2%.

Key statistics

Market cap
$2.03B
Forward P/E
0.0
P/B
15.70
Book value
$0.86
EPS (TTM)
$-5.57
52-week high
$18.57
52-week low
$7.48
50-day MA
$13.37
200-day MA
$11.58
Beta
3.14

Analyst view

Analysts rate Biohaven Ltd. a strong buy (15 buy, 1 hold, 0 sell out of 16) with an average price target of $22.93.

Shareholding

Insiders
11.24%
Institutions
91.44%

Largest institutional holders

FundStake
HHG PLC11.65%
BlackRock Inc7.45%
Suvretta Capital Management, LLC6.83%
Stifel Financial Corp6.60%
State Street Corp4.40%
TCG Crossover Management, LLC3.08%
StemPoint Capital LP2.12%
Royalty Pharma Sub-Manager, LLC1.95%

Recent filings & reports

DocumentDate
Board / officer change · Q3 20262026-07-09
Reg FD disclosure · Q2 20262026-05-27
Company announcement · Q2 20262026-05-05
Quarterly report · Q1 20262026-05-04
Results announced · Q2 20262026-05-04
Proxy statement · Q2 20262026-03-13
Annual report FY20252026-03-02
Quarterly report · Q3 20252025-11-10

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Biohaven Ltd. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.